Home
News
默认头像

Pfizer Boost FY24 Adj. EPS Outlook - Update

2024-06-07MyfxbookMyfxbook
While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook.
Pfizer Boost FY24 Adj. EPS Outlook - Update

(RTTNews) - While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook.

For fiscal 2024, the company now projects adjusted earnings in a range of $2.15 to $2.35 per share, up from the prior guidance range of $2.05 and $2.25 per share.

However, the company continues to project revenues between $58.5 billion and $61.5 billion, with revenues of about $5 billion for Comirnaty, about $3 billion for Paxlovid and about $3.1 billion from legacy Seagen.

On average, 23 analysts polled by Thomson Reuters expect the company to report earnings of $2.21 per share on revenues of $60.02 billion for the year. Analysts' estimates typically exclude special items.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Disclaimers

The article is sourced from Myfxbook with the original source credited. The views expressed herein are not affiliated with FXOR; readers are encouraged to approach the content rationally. Copyright belongs to the original author. If unintentional infringement upon media or personal intellectual property rights has occurred, please contact us, and we will promptly remove the content. FXOR merely provides information storage services. The article is compiled and released by FXOR; reprints must indicate the original source.